LIBRETTO-431
LIBRETTO-431: Randomized Phase III Trial of First-line Selpercatinib vs Chemotherapy Plus Pembrolizumab in RET Fusion‒Positive NSCLC

Released: October 24, 2023

Activity

Progress
1
Course Completed